Compare IONQ Inc (IONQ) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IONQ Inc vs TransMedics Group Inc — how do they compare? IONQ Inc trades at $39.87 (market cap $15.98B), while TransMedics Group Inc trades at $78.15 (market cap $2.74B). The key difference: IONQ Inc is far larger — about 5.8× TransMedics Group Inc's market cap, and TransMedics Group Inc is more actively traded (949,331 versus 22,848,240). Which is the better fit depends on your goals — on Pluang, investors hold IONQ Inc for 33 Days and TransMedics Group Inc for 24 Days on average.
| IONQ | TMDX | |
|---|---|---|
Market Cap | $15.98B | $2.74B |
Volume | 22,848,240 | 949,331 |
Sector | Technology | Health |
52-Week High | $82.09 | $150.42 |
52-Week Low | $26.59 | $61.99 |
Typical Hold Time | 33 Days | 24 Days |
Enterprise Value | $13.92B | $3.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IONQ trades at $39.63, down 4.14% today, with a bearish technical signal despite oscillators showing some bullish momentum. The company reported revenue of $130.02M in 2025 but posted a net loss of $510.38M, reflecting negative profit margins of -553.27%. Recent earnings showed mixed results with a Q2 2026 miss after two consecutive beats. Analyst sentiment remains divided with a 50/50 buy/hold split but a consensus price target of $62.75 suggesting significant upside potential from current levels.
The outlook for IONQ hinges on scaling quantum computing technology to justify its premium valuation (P/S 54.74). While strong revenue growth projections and strategic partnerships offer long-term potential, investors face substantial risks from persistent losses, cash burn, and intense competition in the emerging quantum computing sector.
TransMedics Group (TMDX) trades at $78.17, down 3.58% on the day, with a bearish technical signal and mixed earnings history. The company reported strong 2025 results with $605.49M revenue and $190.29M net income, but 2026 projections show margin compression. Recent news highlights insider buying and leadership changes alongside legal investigations into fiduciary duties, creating a complex sentiment backdrop.
The stock offers growth potential with a consensus price target of $99.75, but faces risks from earnings misses, margin pressure, and ongoing legal scrutiny. Analyst consensus remains bullish with 69% buy ratings, yet investors must weigh robust profitability metrics against execution and regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About IONQ Inc
IonQ is a leader in quantum computing, developing world-class quantum systems. Its technology aims to solve complex problems across finance, healthcare, and materials science that are beyond classical computers.
Read more on IONQ →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
